SBC Medical Group Holdings (NasdaqGM:SBC) Conference January 21, 2026 04:00 PM ET Company ParticipantsHikaru Fukui - Head of Investor RelationsStephen Rogers - Head of Global Planning and StrategyConference Call ParticipantsAashi Shah - AnalystAashi ShahGood afternoon, everyone. Welcome to the Day 1 of the Sidoti Microcap Conference. My name is Aashi Shah, and I'm an analyst here at Sidoti. With me today, I have SBC Medical Group. It trades under the ticker SBC. Join me in welcoming Hikaru Fukui, Head of IR ...

Summary of Conference Call Records Company: Kneat.com (OTCPK:KSIO.F) Key Points - **Company Overview**: Kneat.com provides digital validation solutions for life sciences, ensuring high-quality manufacturing processes for therapies. The platform is designed to be user-friendly and configurable, allowing customers to manage their validation workflows without coding [2][3]. - **Market Position**: Kneat is positioned as a market leader with high customer retention rates. The company reported a net revenue retention rate of 151% at the end of 2024, indicating strong organic growth and customer expansion [4]. - **Growth Strategy**: The company employs a "land and expand" model, starting with one validation process and scaling to multiple processes across various sites. Notably, one customer expanded to seven workflows across 27 sites with 12,000 users [6]. - **Customer Base**: Kneat counts eight of the top ten largest life science companies as customers, with several experiencing significant expansion rates of 70% to 100% [6][7]. - **Total Addressable Market (TAM)**: The company estimates a total addressable market of $2 billion, indicating substantial growth opportunities within its existing customer base [8]. - **Competitive Landscape**: Kneat has a strong competitive advantage, evidenced by a 98% user satisfaction rate according to the G2 report, significantly higher than competitors [9][10]. The company has successfully established itself in a new category of validation solutions, although new competitors are entering the market [8]. - **Financial Outlook**: Kneat expects to reach break-even by 2026, supported by a founder-led executive team with extensive experience in pharmaceutical manufacturing [5]. - **AI Integration**: The company is actively integrating AI into its platform to enhance efficiency and effectiveness in software development and operations, while ensuring compliance with regulatory standards [11][12]. Company: Region Biopharma Inc. (OTC: RGBP) Key Points - **Company Focus**: Region Biopharma is a biotech company specializing in autologous cell therapies, RNA and DNA-based immunotherapy, and small molecules targeting immune oncology and autoimmune diseases [13]. - **Stock Distribution**: The company announced a dividend distribution of Series A preferred shares to shareholders, aimed at increasing liquidity and mitigating recent stock price declines [15][16]. - **Market Conditions**: The stock price has dropped significantly, prompting the company to adjust the pricing of its new Reg A stock from $0.01 to $0.000045 per share [19]. - **Clinical Trials Update**: Region Biopharma is exploring alternative contract research organizations (CROs) due to unexpected cost increases from their current CRO, which doubled the price for clinical phase 1 trials [20]. - **FDA Grant Application**: The company has filed for an FDA grant but is awaiting feedback, which may be delayed due to a government shutdown [24]. Company: Stallion Uranium Corp. (OTC QB: STLNF, TSXV: STUD) Key Points - **Industry Context**: The company emphasizes the growing demand for uranium due to anticipated reactor builds and declining production, positioning itself in the high-grade Athabasca Basin [27][28]. - **Exploration and Financing**: Stallion Uranium has raised over CAD 24 million and is fully financed to begin drilling on a 1,700 square kilometer land package in the Athabasca Basin [29]. - **Drilling Strategy**: The company plans to employ a methodical approach to exploration, having completed additional surveys that indicate promising geological conditions for uranium discovery [30]. - **Team Experience**: The management team has a strong track record of high-grade discoveries in the region, with a history of significant shareholder returns [33]. - **Upcoming Developments**: The company is preparing to mobilize drilling rigs and expects to release drilling results in early February [36]. Additional Insights - **Regulatory Compliance**: Both Kneat and Region Biopharma emphasize the importance of regulatory compliance in their operations, particularly in the life sciences and biotech sectors [2][11][24]. - **Market Trends**: The discussions highlight a broader trend in the life sciences and biotech industries towards digital solutions and innovative therapies, reflecting the evolving landscape of healthcare [2][13][27].

Sid Charbonnet President, Seemann Composites Karman Space & Defense Expands into High-Priority Maritime Defense Market with Agreement to Acquire Seemann Composites and Materials Sciences January 21, 2026 Tony Koblinski Chief Executive Officer Mike Willis Chief Financial Officer Chief Operating Officer Steven Gitlin Vice President Investor Relations Jonathan Beaudoin 21 JAN, 2026 Forward-Looking Statements This presentation may contain "forward-looking statements" within the meaning of Section 27A of the Sec ...

Fourth Quarter 2025 Earnings Non-GAAP Financial Data Disclosure This presentation, including documents incorporated herein by reference, will contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to risks and un ...

Clene Inc. Conference Call Summary Company Overview - Clene Inc. is a clinical stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including ALS (Amyotrophic Lateral Sclerosis) and MS (Multiple Sclerosis) [1] Key Accomplishments and FDA Interactions - Clene has achieved an in-person meeting with the FDA this quarter, marking the fifth meeting in 14 months to discuss extensive biomarker and survival data [2] - The company presented significant biomarker analyses showing reductions in neurofilament and GFAP (glial fibrillary acidic protein), which are associated with longer survival in ALS patients [3][4] - Clene aims to file a new drug application (NDA) under the accelerated approval pathway, utilizing biomarker data as a surrogate endpoint due to missed primary endpoints in previous studies [5][6] Biomarker Data and Clinical Evidence - The company has demonstrated that reductions in neurofilament levels are quantitatively associated with improved survival, with a noted reduction of 9%-10% linked to lower mortality risk [8] - Clene is pursuing a three-pronged approach to validate the biomarker benefits, including proving substantial biomarker benefit, establishing an independent association with mortality, and demonstrating consistent clinical benefits [7][9] Future Plans and Timeline - The FDA meeting is scheduled for later this quarter, with the intent to file the NDA in the second quarter of 2024 if the FDA concurs with the data presented [11][12] - If accepted, commercialization could begin by early 2025, with aspirations to approve CNM-Au8 for ALS patients [13] Financing and Cash Runway - Clene raised approximately $6 million at a price of $6.50 per share through a tranche financing, extending its cash runway by an additional quarter [17] - Future tranches are planned, with potential raises of $7 million at $7 per share and $15 million at a $12.50 strike price upon approval [18] Industry Context and Need for New Treatments - There are over 30,000 ALS patients in the U.S., with a uniform mortality rate of 2-4 years without treatment, highlighting the urgent need for new drugs [19] - Clene is also working to reauthorize funding for ALS research at the Congressional level, emphasizing the critical need for advancements in treatment options [19] Conclusion - Clene Inc. is positioned to make significant strides in ALS treatment through its ongoing FDA interactions and biomarker research, with a clear plan for future drug application and funding strategies [20]

Summary of Global Crossing Airlines Group Conference Call Company Overview - **Company Name**: Global Crossing Airlines Group (OTCPK: JETM.F) - **Industry**: Charter Airline - **Established**: February 2020, certified as an airline in August 2021 - **Current Fleet**: 18 operating aircraft, plans for growth [4][10] Key Financial Metrics - **Valuation**: Trading at 2 times EBITDA, compared to peers sold for 6.9 times EBITDA [2] - **Market Size**: U.S. charter market estimated at $3.9 billion, cargo market at $5.8 billion, totaling approximately $9 billion revenue opportunity [10] - **2024 Revenue**: $223 million [10] - **Q3 Financials**: $58 million in revenue, $18.9 million EBITDA, 9,900 block hours flown [21] Business Model - **Charter Operations**: Operates on an ACMI (Aircraft Crew Maintenance Insurance) basis, which is more prevalent in Europe [7][12] - **Cost Structure**: No fixed schedule; revenue based on hourly rates for flights, with fuel and crew costs passed through to customers [12][13] - **Profitability Focus**: Aims for $300,000 to $400,000 operating income per aircraft per month [13] Growth Strategy - **Fleet Expansion**: Plans to grow from 20 aircraft, with current leasing strategy to avoid high lease rates [16][17] - **Base Locations**: Established bases in Miami, Alexandria, Louisiana, and Harlingen, Texas to enhance operational efficiency and competitiveness [18] - **Market Reach**: Flown to over 450 cities in 67 countries, with flexibility to adapt to customer needs [19][20] Competitive Landscape - **Market Position**: Largest charter operator in the U.S., capitalizing on competitors' failures due to high debt and service delivery issues [9][40] - **Risk Management**: Maintains a disciplined approach to fleet management and maintenance reserves to avoid operational pitfalls [41][42] Operational Insights - **Pilot Recruitment**: Offers unique benefits to pilots, including a Gateway Program allowing flexible living arrangements, which helps attract experienced captains [33][34] - **Maintenance Strategy**: Leases all aircraft, paying into maintenance reserves to ensure funds are available for heavy maintenance checks [41] Future Outlook - **Profitability Goals**: Focus on improving utilization and profitability through high-margin ACMI work, while navigating a weak cargo market [26] - **Investment Highlights**: Fastest-growing charter airline with a strong employee investment and belief in the company's future [28][30] Conclusion - **Overall Assessment**: The company believes its valuation does not reflect its growth potential and operational achievements, encouraging investors to consider the unit economics of adding aircraft to the fleet [43]

Financial Data and Key Metrics Changes - The fiscal year 2025 is viewed as a turning point for the company, marking a transformation from a lighting and lighting controls company to an industrial control company [12] - The lighting business continued to perform well despite market challenges, maintaining its position as the best-performing lighting company globally [12] Business Line Data and Key Metrics Changes - The acquisition of QSC has contributed to the growth of the AIS business, establishing it as a thriving second business that is positively impacting outcomes in various spaces [12] Market Data and Key Metrics Changes - The company faced significant market challenges and policy upheaval but managed to sustain strong performance in its lighting segment [12] Company Strategy and Development Direction - The company is focused on long-term growth, positioning itself as an innovator and disruptor in the industry, aiming to create stakeholder value and compound shareholder wealth [3] Management's Comments on Operating Environment and Future Outlook - Management expressed satisfaction with the operational performance during the year and is optimistic about the foundation being built for fiscal 2026 and beyond [12] Other Important Information - The company successfully elected its board of directors and ratified the appointment of Ernst & Young as its independent registered public accounting firm for the fiscal year ending August 31, 2026 [10] Q&A Session Summary Question: What was the most important thing that happened this year? - Management highlighted the transformation of the company and the successful integration of QSC, along with the continued strong performance of the lighting business despite challenges [12]

Financial Data and Key Metrics Changes - The fiscal year 2025 is viewed as a turning point in the company's transformation from a lighting and lighting controls company to an industrial control company, indicating a strategic shift in focus [12] - The company reported that its lighting business continued to be the best-performing lighting company globally despite significant market challenges and policy upheaval [12] Business Line Data and Key Metrics Changes - The acquisition of QSC and the growth of the AIS business have resulted in a thriving second business that is changing outcomes in various spaces, showcasing diversification in revenue streams [12] Market Data and Key Metrics Changes - The company faced significant market challenges and policy upheaval but managed to maintain strong performance in its lighting segment, indicating resilience in a volatile market [12] Company Strategy and Development Direction - The company is positioned for long-term growth, emphasizing innovation, disruption, and stakeholder value creation as core components of its strategy [3] - The integration of QSC is highlighted as a successful move that enhances the company's operational capabilities [3] Management's Comments on Operating Environment and Future Outlook - Management expressed satisfaction with the operational performance during the year and optimism about the foundation being built for fiscal 2026 and beyond [12] Other Important Information - The company successfully elected its board of directors and ratified the appointment of Ernst & Young as its independent registered public accounting firm for the fiscal year ending August 31, 2026 [10] Q&A Session Summary Question: What was the most important thing that happened this year? - The acquisition of QSC and the growth of the AIS business were identified as pivotal developments, marking a significant transformation for the company [12]

Summary of Simulations Plus Investor Day - January 21, 2026 Company Overview - **Company**: Simulations Plus (NasdaqGS:SLP) - **Industry**: Biopharmaceutical modeling and simulation - **Focus**: Drug development, commercialization, and scientific consulting Core Points and Arguments Industry Transformation - The biopharma industry is undergoing significant changes, including: - Adoption of AI - Shift towards cloud-native scientific computation - Move away from animal testing - Increased reliance on model-informed drug development [2][12][50] Company Vision and Mission - **Vision**: Improve quality of life through innovative solutions - **Mission**: Create value for clients by accelerating the discovery, development, and commercialization of pharmaceuticals through science-based software and consulting solutions [3][2] Unique Value Proposition - Simulations Plus differentiates itself through: - A combination of scientific excellence and technological innovation - A robust suite of software products including GastroPlus, MonolixSuite, ADMET Predictor, DILIsym, and Thileys [4][5] - The company is evolving from point solutions to an integrated cloud-enabled ecosystem [5] Market Opportunity - Total Addressable Market (TAM) is approximately $12.5 billion: - $4 billion in traditional biosimulation - $8.5 billion in clinical trial training and medical communications [6] Client Needs and Industry Pressures - Clients face pressures from: - Economic factors increasing the cost and complexity of drug development - Scientific complexity requiring advanced modeling techniques - Technological expectations for integrated digital infrastructure [10][11][12] Regulatory Environment - Regulatory agencies are pushing for broader use of model-informed drug development and non-animal methodologies, which aligns with Simulations Plus's offerings [12][56] Strategic Shift - The company is transitioning from a tool provider to an ecosystem partner, focusing on integrated workflows and AI-assisted solutions [14][28] Additional Important Insights Product Strategy and Roadmap - The company is building a unified AI-orchestrated ecosystem that connects various aspects of drug development [20][25] - The architecture includes: - Validated modeling engines - Composition layer for data standardization - Grounded intelligence layer with AI copilots - Orchestration layer for automating workflows [21][22][24] Services and Consulting - Simulations Plus's services complement its product offerings by providing scientific consulting that informs software enhancements and optimizes workflows [33][34] - The consulting teams help clients navigate complex drug development decisions, reducing uncertainty and costs [34][35] Case Studies - Case studies illustrate the effectiveness of Simulations Plus's approach in reducing development timelines and costs while improving clinical trial success rates [41][43] Future Growth and Revenue Opportunities - The acquisition of Pro-ficiency has doubled the TAM and is expected to contribute to future growth [54][55] - The company anticipates increased demand for simulation and modeling services driven by FDA's NAMs guidance [56][58] Pricing Evolution - The company is evolving its pricing strategy to reflect the added value of its integrated ecosystem, with new monetization opportunities expected as the ecosystem matures [29][30] Conclusion - Simulations Plus is well-positioned to lead in the evolving landscape of model-informed drug development, leveraging its scientific expertise, technological innovations, and strategic partnerships to create a cohesive platform that meets the industry's growing demands [53]

Financial Data and Key Metrics Changes - The company reported significant growth in fiscal year 2025, marking a turning point in its transformation from a lighting and lighting controls company to an industrial control company [13] - The acquisition of QSC and the growth of the AIS business contributed to a thriving second business, enhancing overall performance [13] Business Line Data and Key Metrics Changes - The lighting business continued to perform exceptionally well, maintaining its position as the best-performing lighting company globally despite market challenges [13] Market Data and Key Metrics Changes - The company faced significant market challenges and policy upheaval but managed to navigate these effectively, showcasing resilience in its operations [13] Company Strategy and Development Direction - The company is focused on long-term growth, positioning itself as an innovator and disruptor in the industry, aiming to create stakeholder value and compound shareholder wealth [3] - The integration of QSC is a key part of the company's strategy to enhance its industrial control capabilities [13] Management's Comments on Operating Environment and Future Outlook - Management expressed satisfaction with the company's operations in fiscal year 2025 and is optimistic about the foundation being built for fiscal 2026 and beyond [13] Other Important Information - The company successfully ratified the appointment of Ernst & Young as its independent registered public accounting firm for fiscal year 2026 [11] Q&A Session Summary Question: What was the most important thing that happened this year? - Management highlighted the transformation into an industrial control company as a significant milestone, driven by the acquisition of QSC and the growth of the AIS business, while also noting the strong performance of the lighting business amidst challenges [13]